GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Shiller PE Ratio

ESLA (Estrella Immunopharma) Shiller PE Ratio : (As of Dec. 15, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Shiller PE Ratio?

Estrella Immunopharma does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Estrella Immunopharma Shiller PE Ratio Historical Data

The historical data trend for Estrella Immunopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Shiller PE Ratio Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Shiller PE Ratio
- - - -

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Estrella Immunopharma's Shiller PE Ratio

For the Biotechnology subindustry, Estrella Immunopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Shiller PE Ratio falls into.



Estrella Immunopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Estrella Immunopharma does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Estrella Immunopharma  (NAS:ESLA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Estrella Immunopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.